drugset / Trial / NCT06161025
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RandomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Timeline
- Start
- 2024-02-27
- Primary completion
- 2028-02-29
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PLD | Unknown | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Raludotatug Deruxtecan | Other / unclassified | 4.8 mg/kg | Intravenous |
| Subject | Raludotatug Deruxtecan | Other / unclassified | 5.6 mg/kg | Intravenous |
| Subject | Raludotatug Deruxtecan | Other / unclassified | 6.4 mg/kg | Intravenous |
| Comparator | Topotecan | Small molecule | — | Intravenous |
Indications
No indication recorded.